Insulin priming effect on estradiol-induced breast cancer metabolism and growth

Peninah M. Wairagu, Ai N.H. Phan, Min Kyu Kim, Jeongwoo Han, Hyun Won Kim, Jong Whan Choi, Kiwoo Kim, Seungkuy Cha, Kwang Hwa Park, Yangsik Jeong

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Diabetes is a risk factor for breast cancer development and is associated with poor prognosis for breast cancer patients. However, the molecular and biochemical mechanisms underlying the association between diabetes and breast cancer have not been fully elucidated. Here, we investigated estradiol response in MCF-7 breast cancer cells with or without chronic exposure to insulin. We found that insulin priming is necessary and specific for estradiol-induced cancer cell growth, and induces anaplerotic shunting of glucose into macromolecule biosynthesis in the estradiol treated cells. Treatment with ERK or Akt specific inhibitors, U0126 or LY294002, respectively, suppressed estradiol-induced growth. Interestingly, molecular analysis revealed that estradiol treatment markedly increases expression of cyclin A and B, and decreases p21 and p27 in the insulin-primed cells. In addition, estradiol treatment activated metabolic genes in pentose phosphate (PPP) and serine biosynthesis pathways in the insulin-primed cells while insulin priming decreased metabolic gene expression associated with glucose catabolism in the breast cancer cells. Finally, we found that anti-diabetic drug metformin and AMPK ligand AICAR, but not thiazolidinediones (TZDs), specifically suppress the estradiol-induced cellular growth in the insulin-primed cells. These findings suggest that estrogen receptor (ER) activation under chronic hyperinsulinemic condition increases breast cancer growth through the modulation of cell cycle and apoptotic factors and nutrient metabolism, and further provide a mechanistic evidence for the clinical benefit of metformin use for ER-positive breast cancer patients with diabetes.

Original languageEnglish
Pages (from-to)484-492
Number of pages9
JournalCancer Biology and Therapy
Volume16
Issue number3
DOIs
Publication statusPublished - 2015 Mar 1

Fingerprint

Estradiol
Insulin
Breast Neoplasms
Growth
Metformin
Estrogen Receptors
Cyclin B
Pentoses
Phosphoserine
Glucose
Thiazolidinediones
Cyclin A
AMP-Activated Protein Kinases
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Cell Cycle
Therapeutics
Ligands
Gene Expression
Food
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Wairagu, P. M., Phan, A. N. H., Kim, M. K., Han, J., Kim, H. W., Choi, J. W., ... Jeong, Y. (2015). Insulin priming effect on estradiol-induced breast cancer metabolism and growth. Cancer Biology and Therapy, 16(3), 484-492. https://doi.org/10.1080/15384047.2015.1016660
Wairagu, Peninah M. ; Phan, Ai N.H. ; Kim, Min Kyu ; Han, Jeongwoo ; Kim, Hyun Won ; Choi, Jong Whan ; Kim, Kiwoo ; Cha, Seungkuy ; Park, Kwang Hwa ; Jeong, Yangsik. / Insulin priming effect on estradiol-induced breast cancer metabolism and growth. In: Cancer Biology and Therapy. 2015 ; Vol. 16, No. 3. pp. 484-492.
@article{a0c4d440dcca4fd98b5213cc2a38dfdc,
title = "Insulin priming effect on estradiol-induced breast cancer metabolism and growth",
abstract = "Diabetes is a risk factor for breast cancer development and is associated with poor prognosis for breast cancer patients. However, the molecular and biochemical mechanisms underlying the association between diabetes and breast cancer have not been fully elucidated. Here, we investigated estradiol response in MCF-7 breast cancer cells with or without chronic exposure to insulin. We found that insulin priming is necessary and specific for estradiol-induced cancer cell growth, and induces anaplerotic shunting of glucose into macromolecule biosynthesis in the estradiol treated cells. Treatment with ERK or Akt specific inhibitors, U0126 or LY294002, respectively, suppressed estradiol-induced growth. Interestingly, molecular analysis revealed that estradiol treatment markedly increases expression of cyclin A and B, and decreases p21 and p27 in the insulin-primed cells. In addition, estradiol treatment activated metabolic genes in pentose phosphate (PPP) and serine biosynthesis pathways in the insulin-primed cells while insulin priming decreased metabolic gene expression associated with glucose catabolism in the breast cancer cells. Finally, we found that anti-diabetic drug metformin and AMPK ligand AICAR, but not thiazolidinediones (TZDs), specifically suppress the estradiol-induced cellular growth in the insulin-primed cells. These findings suggest that estrogen receptor (ER) activation under chronic hyperinsulinemic condition increases breast cancer growth through the modulation of cell cycle and apoptotic factors and nutrient metabolism, and further provide a mechanistic evidence for the clinical benefit of metformin use for ER-positive breast cancer patients with diabetes.",
author = "Wairagu, {Peninah M.} and Phan, {Ai N.H.} and Kim, {Min Kyu} and Jeongwoo Han and Kim, {Hyun Won} and Choi, {Jong Whan} and Kiwoo Kim and Seungkuy Cha and Park, {Kwang Hwa} and Yangsik Jeong",
year = "2015",
month = "3",
day = "1",
doi = "10.1080/15384047.2015.1016660",
language = "English",
volume = "16",
pages = "484--492",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

Wairagu, PM, Phan, ANH, Kim, MK, Han, J, Kim, HW, Choi, JW, Kim, K, Cha, S, Park, KH & Jeong, Y 2015, 'Insulin priming effect on estradiol-induced breast cancer metabolism and growth', Cancer Biology and Therapy, vol. 16, no. 3, pp. 484-492. https://doi.org/10.1080/15384047.2015.1016660

Insulin priming effect on estradiol-induced breast cancer metabolism and growth. / Wairagu, Peninah M.; Phan, Ai N.H.; Kim, Min Kyu; Han, Jeongwoo; Kim, Hyun Won; Choi, Jong Whan; Kim, Kiwoo; Cha, Seungkuy; Park, Kwang Hwa; Jeong, Yangsik.

In: Cancer Biology and Therapy, Vol. 16, No. 3, 01.03.2015, p. 484-492.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Insulin priming effect on estradiol-induced breast cancer metabolism and growth

AU - Wairagu, Peninah M.

AU - Phan, Ai N.H.

AU - Kim, Min Kyu

AU - Han, Jeongwoo

AU - Kim, Hyun Won

AU - Choi, Jong Whan

AU - Kim, Kiwoo

AU - Cha, Seungkuy

AU - Park, Kwang Hwa

AU - Jeong, Yangsik

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Diabetes is a risk factor for breast cancer development and is associated with poor prognosis for breast cancer patients. However, the molecular and biochemical mechanisms underlying the association between diabetes and breast cancer have not been fully elucidated. Here, we investigated estradiol response in MCF-7 breast cancer cells with or without chronic exposure to insulin. We found that insulin priming is necessary and specific for estradiol-induced cancer cell growth, and induces anaplerotic shunting of glucose into macromolecule biosynthesis in the estradiol treated cells. Treatment with ERK or Akt specific inhibitors, U0126 or LY294002, respectively, suppressed estradiol-induced growth. Interestingly, molecular analysis revealed that estradiol treatment markedly increases expression of cyclin A and B, and decreases p21 and p27 in the insulin-primed cells. In addition, estradiol treatment activated metabolic genes in pentose phosphate (PPP) and serine biosynthesis pathways in the insulin-primed cells while insulin priming decreased metabolic gene expression associated with glucose catabolism in the breast cancer cells. Finally, we found that anti-diabetic drug metformin and AMPK ligand AICAR, but not thiazolidinediones (TZDs), specifically suppress the estradiol-induced cellular growth in the insulin-primed cells. These findings suggest that estrogen receptor (ER) activation under chronic hyperinsulinemic condition increases breast cancer growth through the modulation of cell cycle and apoptotic factors and nutrient metabolism, and further provide a mechanistic evidence for the clinical benefit of metformin use for ER-positive breast cancer patients with diabetes.

AB - Diabetes is a risk factor for breast cancer development and is associated with poor prognosis for breast cancer patients. However, the molecular and biochemical mechanisms underlying the association between diabetes and breast cancer have not been fully elucidated. Here, we investigated estradiol response in MCF-7 breast cancer cells with or without chronic exposure to insulin. We found that insulin priming is necessary and specific for estradiol-induced cancer cell growth, and induces anaplerotic shunting of glucose into macromolecule biosynthesis in the estradiol treated cells. Treatment with ERK or Akt specific inhibitors, U0126 or LY294002, respectively, suppressed estradiol-induced growth. Interestingly, molecular analysis revealed that estradiol treatment markedly increases expression of cyclin A and B, and decreases p21 and p27 in the insulin-primed cells. In addition, estradiol treatment activated metabolic genes in pentose phosphate (PPP) and serine biosynthesis pathways in the insulin-primed cells while insulin priming decreased metabolic gene expression associated with glucose catabolism in the breast cancer cells. Finally, we found that anti-diabetic drug metformin and AMPK ligand AICAR, but not thiazolidinediones (TZDs), specifically suppress the estradiol-induced cellular growth in the insulin-primed cells. These findings suggest that estrogen receptor (ER) activation under chronic hyperinsulinemic condition increases breast cancer growth through the modulation of cell cycle and apoptotic factors and nutrient metabolism, and further provide a mechanistic evidence for the clinical benefit of metformin use for ER-positive breast cancer patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84926334376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926334376&partnerID=8YFLogxK

U2 - 10.1080/15384047.2015.1016660

DO - 10.1080/15384047.2015.1016660

M3 - Article

C2 - 25701261

AN - SCOPUS:84926334376

VL - 16

SP - 484

EP - 492

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -